EGFR and non-small cell lung carcinoma: The top 20 significantly enriched pathways of YYD against NSCLC were shown as a bubble chart (Figure 4(b)), including pathways in cancer, proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-AKT signaling pathway, chemical carcinogenesis-reactive oxygen species, and ErbB signaling pathway.